There is accumulating pre-clinical evidence suggesting that T-cell infiltration and activation through modulation of the STING/adenosine pathways and epigenetic rewiring of the tumor in combination with chemo/radiotherapy may have a clinically positive impact on patient survival and outcome. The gene discussed is STING1; the disease is neoplasm.